Endogenous Intact PTH is Suppressed during Teriparatide (rhPTH 1-34) Administration in Postmenopausal Women with Established Osteoporosis

• ANASTASILAKIS Athanasios D.

  Department of Endocrinology, Hippocration General Hospital

• POLYZOS Stergios A.

  Department of Endocrinology, Hippocration General Hospital

• GOULIS Dimitrios G.

  Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki

• SLAVAKIS Aristides

  Department of Microbiology, Hippocration General Hospital

• EFSTATHIADOU Zoe

  Department of Endocrinology, Hippocration General Hospital

• KITA Marina

  Department of Endocrinology, Hippocration General Hospital

• KOUKOULIS George

  Department of Internal Medicine, University of Thessalia

• AVRAMIDIS Avraam

  Department of Endocrinology, Hippocration General Hospital

Abstract

Introduction: Teriparatide (recombinant human PTH 1-34/TPTD) is an osteoanabolic agent available for osteoporosis treatment. The aim of this prospective trial was to evaluate the acute and chronic effects of TPTD in endogenous intact PTH (iPTH) levels in postmenopausal women with established osteoporosis. Materials and methods: Thirty-six postmenopausal Caucasian women (age 66.6 1.4 years) with established osteoporosis received TPTD 20 μg once daily for eighteen months. Follow-up was continued for another six months after treatment discontinuation for a total of 24 months. Serum calcium, phosphate, total alkaline phosphatase (ALP) and iPTH were obtained from all women before and one hour, one day, as well as one, six, twelve, 18 and 24 months after treatment initiation. Lumbar spine bone mineral density was measured before, as well as twelve and eighteen months after treatment initiation. Results: iPTH levels decreased from the first hour of treatment, remained suppressed as long as TPTD was administered and increased after treatment discontinuation (p<0.001). Total ALP followed an opposite pattern. Serum calcium remained within normal range. Conclusions: iPTH levels are suppressed rapidly and persistently during TPTD administration whereas they return to baseline after treatment discontinuation; therefore, they can serve as an index of patient's compliance to treatment.<br>

Journal

• Endocrine Journal

  Endocrine Journal 55 (3), 613-616, 2008

  The Japan Endocrine Society

Keywords

• Teriparatide
• Parathyroid hormone
• Osteoporosis treatment

Details

• CRID: 1390282681274356224
• NII Article ID: 10021266779
• NII Book ID: AA10901436
• DOI: 10.1507/endocrj.k07e-123
• ISSN: 13484540
• ISSN: 09188959
• Web Site: http://www.jstage.jst.go.jp/article/endocrj/55/3/55_K07E-123/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2008285046
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
• Abstract License Flag: Disallowed